Stock Update (NYSE:PFE): Pfizer Receives U.S. FDA Accelerated Approval of IBRANCE® (palbociclib)

[Business Wire] – Pfizer Inc. today announced the U.S. Food and Drug Administration has granted accelerated approval of IBRANCE® , in combination with letrozole, for the treatment of postmenopausal women with estrogen receptor-positive, . . . → Read More: Stock Update (NYSE:PFE): Pfizer Receives U.S. FDA Accelerated Approval of IBRANCE® (palbociclib) Similar Articles: Company Update (NYSE:PFE): OPKO and Pfizer Receive Regulatory Clearance for Global Agreement Stock Update: Pfizer Inc (NYSE:PFE) – Pfizer and Breast Cancer Leaders Join Together to Increase Understanding and Dispel Myths about Metastatic Breast Cancer Company Update: Pfizer Inc (NYSE:PFE) – Pfizer Completes Acquisition Of InnoPharma